author-photo

Chia-Cheng Tseng

Chang Gung University

34

Papers

340

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.

2021 Thoracic Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Different Survival Benefit of Osimertinib in Different Sequences: A Real‐World Outcome of Osimertinib Treatment in Pretreated T790M-Positive Advanced NSCLC in Taiwan

2021
Show All
- Source
- Cite
- Save
Citations (0)
Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation

2021 Nutrients
Show All
- Source
- Cite
- Save
Citations (0)
Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real-world study

2021 Thoracic Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Aberrant DNA methylation of the toll-like receptors 2 and 6 genes in patients with obstructive sleep apnea

2020 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (0)
Ventilator Dependence Risk Score for the Prediction of Prolonged Mechanical Ventilation in Patients Who Survive Sepsis/Septic Shock with Respiratory Failure

2018 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (10)
Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors

2017 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (3)
A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases

2016 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (3)
The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors

2016 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (13)
Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.

2016 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (11)